Literature DB >> 27030607

Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study.

Agnès Libois1, Francesco Feoli2, Marcel Nkuize3, Marc Delforge1, Deborah Konopnicki1, Nathan Clumeck1, Stéphane De Wit1.   

Abstract

OBJECTIVE: HIV-positive men who have sex with men (MSM) are at increased risk of anal cancer. We evaluate the risk factors for anal high-grade squamous intraepithelial lesion (HSIL) (the precursor of anal cancer) in HIV-positive MSM.
METHODS: In this cross-sectional study within a cohort, 320 HIV-positive MSM were screened by anal cytology followed by high-resolution anoscopy (HRA) in case of abnormal cytology. Risk factors for anal HSIL were analysed.
RESULTS: Men were mostly middle-aged Caucasians with median CD4+ T lymphocytes of 638 cells/µL, 87% on combined antiretroviral therapy (cART) for a median of 5 years. 198 anal cytology samples were normal. In the 122 patients with abnormal cytology, HRA with biopsies were performed: 12% (n=15) normal, 36% (n=44) anal low-grade squamous intraepithelial lesion (LSIL) and 51% (n=63) anal HSIL. Comparing patients with or without anal HSIL (normal cytology or normal biopsy or LSIL), we found in multivariate analysis significantly fewer anal HSIL in patients with cART ≥24 months (OR 0.32 CI 95% 0.162 to 0.631, p=0.001).
CONCLUSIONS: Prolonged cART (≥24 months) is associated with fewer anal HSIL. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  ANOGENITAL CANCER; ANTIRETROVIRAL THERAPY; GAY MEN; HIV; HPV

Mesh:

Substances:

Year:  2016        PMID: 27030607     DOI: 10.1136/sextrans-2015-052444

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  7 in total

Review 1.  Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.

Authors:  John Berry; Sean C Glasgow
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 2.  Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era.

Authors:  Joel M Palefsky
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

3.  Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions.

Authors:  Jenny C McCloskey; W Martin Kast; James P Flexman; Dugald McCallum; Martyn A French; Michael Phillips
Journal:  Papillomavirus Res       Date:  2017-11-07

4.  Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments.

Authors:  Carmen Hidalgo-Tenorio; Carmen Maria García-Martínez; Juan Pasquau; Mohamed Omar-Mohamed-Balgahata; Miguel López-Ruz; Javier López-Hidalgo; Concepción Gil-Anguita
Journal:  PLoS One       Date:  2021-02-03       Impact factor: 3.240

5.  Risk factors for anal high-grade squamous intraepithelial lesions in HIV-positive MSM: is targeted screening possible?

Authors:  Matthijs L Siegenbeek van Heukelom; Elske Marra; Henry J C de Vries; Maarten F Schim van der Loeff; Jan M Prins
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

Review 6.  Squamous cell anal cancer: Management and therapeutic options.

Authors:  Beatrice Pessia; Lucia Romano; Antonio Giuliani; Gianni Lazzarin; Francesco Carlei; Mario Schietroma
Journal:  Ann Med Surg (Lond)       Date:  2020-05-12

7.  HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.

Authors:  Karen Canfell; Jane J Kim; Shalini Kulasingam; Johannes Berkhof; Ruanne Barnabas; Johannes A Bogaards; Nicole Campos; Chloe Jennett; Monisha Sharma; Kate T Simms; Megan A Smith; Louiza S Velentzis; Marc Brisson; Mark Jit
Journal:  Papillomavirus Res       Date:  2019-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.